{
  "id": 172211,
  "title": "Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge",
  "url": "https://urgent.news/2026/08/05/eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-172211",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-05T10:57:06.000Z",
  "source": {
    "name": "CNBC World",
    "slug": "cnbc-world",
    "url": "https://www.cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly has reported second-quarter earnings and revenue that exceeded estimates, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The company's worldwide revenue for Mounjaro rose 91% to $9.94 billion for the quarter, with U.S. sales reaching $4.8 billion.\n\nAs a result, Eli Lilly has raised its full-year sales outlook. The company now expects 2026 revenue to be between $85 billion and $87 billion, up from its previous guidance of $82 billion to $85 billion.\n\nThe company's adjusted profit is now projected to be between $35.50 and $36.50 per share. Shares of Eli Lilly rose more than 5% in premarket trading following the announcement, according to CNBC.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "CNBC",
        "title": "Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge",
        "url": "https://urgent.news/2026/08/05/eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-171151",
        "published": "2026-08-05T10:57:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}